Natera, Inc. (NASDAQ:NTRA) Stock Position Raised by Blue Trust Inc.

Blue Trust Inc. increased its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 104.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 190 shares of the medical research company’s stock after acquiring an additional 97 shares during the quarter. Blue Trust Inc.’s holdings in Natera were worth $30,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of NTRA. Versant Capital Management Inc raised its position in shares of Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after purchasing an additional 166 shares during the period. Covestor Ltd grew its stake in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after buying an additional 95 shares during the last quarter. GAMMA Investing LLC increased its position in Natera by 32.7% in the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after buying an additional 106 shares during the period. True Wealth Design LLC bought a new stake in Natera in the third quarter valued at $57,000. Finally, Brooklyn Investment Group acquired a new position in shares of Natera during the third quarter valued at $70,000. Institutional investors own 99.90% of the company’s stock.

Insider Activity at Natera

In related news, insider John Fesko sold 663 shares of the company’s stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $177.77, for a total value of $117,861.51. Following the completion of the sale, the insider now owns 156,044 shares in the company, valued at approximately $27,739,941.88. This represents a 0.42 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Roelof Botha sold 87,473 shares of Natera stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $169.12, for a total transaction of $14,793,433.76. Following the transaction, the director now owns 1,224,787 shares in the company, valued at approximately $207,135,977.44. The trade was a 6.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 312,394 shares of company stock worth $52,333,520 in the last quarter. 7.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. The Goldman Sachs Group increased their price objective on shares of Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. JPMorgan Chase & Co. lifted their price target on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Morgan Stanley increased their price objective on Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. TD Cowen lifted their target price on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, Barclays initiated coverage on Natera in a research note on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 price target for the company. One investment analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $165.88.

Natera Trading Down 0.4 %

Shares of NASDAQ:NTRA opened at $172.19 on Tuesday. The stock has a market capitalization of $22.73 billion, a price-to-earnings ratio of -97.84 and a beta of 1.66. Natera, Inc. has a 1-year low of $67.33 and a 1-year high of $183.00. The company has a 50 day moving average price of $167.71 and a 200 day moving average price of $141.47. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.31. The business had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company’s revenue was up 63.9% compared to the same quarter last year. During the same period last year, the company posted ($0.95) EPS. On average, research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.